Cited by 142Nitric Oxide and Endothelin EffectsCardiovascular Health and Disease PreventionAngiogenesis and VEGF in Cancer

The clinical significance of endothelial dysfunction

Landmesser, Ulf, Drexler, Helmut·2005·Current Opinion in Cardiology

Abstract

PURPOSE OF REVIEW: Endothelial dysfunction is thought to play a pivotal role in the development, progression, and clinical complications of atherosclerosis. Several recent studies have addressed the clinical implications of endothelial dysfunction for cardiovascular events, atherosclerosis, restenosis, and heart failure. Novel findings with respect to endothelial progenitor cells and their alteration by cardiovascular risk factors are characterized and potential therapeutic interventions to improve endothelial and endothelial progenitor cell function are discussed. RECENT FINDINGS: Over the past 5 years evidence has accumulated from clinical studies for a close association of the degree of endothelial dysfunction and clinical cardiovascular events in patients with cardiovascular risk factors, coronary disease, acute coronary syndrome, or heart failure. Understanding of the mechanisms leading to endothelial dysfunction has improved, including the notion that dysfunctional endothelial nitric oxide synthase, in part due to deficiency of the endothelial nitric oxide synthase cofactor tetrahydrobiopterin, likely plays an important role. Major progress has been made in understanding the role of endothelial progenitor cells, which likely contribute to both ischemia-induced neovascularization and endothelial regeneration after injury. Endothelial progenitor cell function is altered in patients with cardiovascular risk factors. SUMMARY: Recent research on endothelial and endothelial progenitor cell dysfunction supports their clinical significance and has led to important insights in the pathophysiology of cardiovascular disease and at the same time provides an important opportunity to develop novel therapeutic approaches. Endothelial function represents a valuable surrogate endpoint to assess the impact of therapeutic interventions.

Integrity signals

Registry

Crossref · 10.1097/01.hco.0000179821.11071.79

Cites

58 of 58 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Landmesser, U., & Drexler, H.
Affiliations
Medizinische Hochschule Hannover (DE)
Corresponding author
  • Landmesser, Ulf
  • Drexler, Helmut
Venue
Current Opinion in Cardiology
Published
2005-11
Volume
20
Issue
6
Pages
547-551
ISSN
0268-4705 (ISSN-L)
OpenAlex
W2089853948
Cited by
142
References
57
Citations by year
2025: 1 · 2024: 3 · 2023: 4 · 2022: 5 · 2021: 2 · 2020: 7 · 2019: 5 · 2018: 5 · 2017: 6 · 2016: 9 · 2015: 4 · 2014: 8 · 2013: 11 · 2012: 12
FWCI
1.00
Type
journal article
Language
en
Open access
closed
Locations
  • Current Opinion in Cardiology (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Physiology › Nitric Oxide and Endothelin Effects
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiovascular Health and Disease Prevention
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Angiogenesis and VEGF in Cancer
Keywords
endothelial dysfunction, endothelial progenitor cells, atherosclerosis, cardiovascular risk factors, endothelial nitric oxide synthase, tetrahydrobiopterin, acute coronary syndrome, coronary disease, restenosis, heart failure, neovascularization, re-endothelialization, surrogate endpoints, endothelial function
MeSH terms
Angiotensin-Converting Enzyme Inhibitors, Cardiovascular Diseases, Endothelium, Vascular, Heart Failure, Humans, Life Style, Risk Factors, Stem Cells, Oxidative Stress, Nitric Oxide Synthase, Hydroxymethylglutaryl-CoA Reductase Inhibitors, Angiotensin II Type 1 Receptor Blockers, Atherosclerosis

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review